| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Phase 3 CoMpass trial on track for topline data in 2H 2027; all participants have completed treatment visits |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities +2 more
Phase 3 CoMpass trial fully enrolled with 108 patients, exceeding enrollment target; on track for topline data in 2H 2027 |
| 05 Aug 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On August 5, 2026, Aura Biosciences, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). As of June 12, 2026, the record date for the Special Meeting, there were 103,436,416 shares of the Company’s common... |
| 08 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Aura Biosciences, Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-... |
| 11 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 11, 2026, Aura Biosciences, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The proposals set forth below were submitted to the stockholders at the Annual Meeting, with each such proposal... |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data |
| 05 May 2026 |
8-K: Entry into a Material Definitive Agreement
1. INTRODUCTORY. Aura Biosciences, Inc., a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the “Underwriters,” or, each, an “Underwr... |
| 04 May 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
On April 30, 2026, Aura Biosciences, Inc. (the “Company”) and Matrix Capital Management Master Fund, LP (“Matrix”) entered into a stock purchase agreement (the “Repurchase Agreement”) pursuant to which the Company has agreed to repurchas... |
| 04 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure +1 more
Natalie Holles, seasoned industry executive with significant rare disease operational and commercialization experience, appointed Chief Executive Officer and President and member of the Board of Directors |
| 30 Mar 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition; Other Events
Aura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint |
| 13 Aug 2025 |
8-K: Results of Operations and Financial Condition; Other Events
Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC) |
| 18 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 17, 2025, Aura Biosciences, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The proposals set forth below were submitted to the stockholders at the Annual Meeting, with each such proposal... |
| 16 May 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
1. INTRODUCTORY. Aura Biosciences, Inc., a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the “Underwriters,” or, each, an “Underwr... |
| 15 May 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025 |
| 02 Apr 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
BOSTON, April 2, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment ... |
| 24 Mar 2025 |
8-K: Results of Operations and Financial Condition; Other Events
Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; Supports Front-Line Treatment Potential |
| 12 Nov 2024 |
8-K: Results of Operations and Financial Condition; Other Events
Positive Phase 2 End of Study Data with Bel-sar in Early-Stage Choroidal Melanoma; Ongoing Phase 3 CoMpass Trial Recently Received Authorization to Start Enrolling Patients in Europe |
| 17 Oct 2024 |
8-K: Regulation FD Disclosure; Other Events
Exhibit 99.2 To innovate the future of cancer care to cure patients and preserve organ function October 17, 2024 1 |
| 27 Sep 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Loading...